Sept 10 (Reuters) - Soleno Therapeutics ( SLNO )
reported on Wednesday the death of a 17 year old male who was on
the company's treatment for patients who experience feelings of
intense and persistent hunger.
The company said the treating physician has reported that
the death is not related to the treatment.